United Therapeutics Executives Sell Over 13,726 Shares at $483–$535 Prices
Martine Rothblatt sold 516 United Therapeutics shares at $534.99 each, leaving her with 8,414 shares. Ray Kurzweil sold 4,910 shares at $489.02, reducing his holdings to 12,670, and EVP Paul Mahon sold 8,300 shares at $483.16, leaving 36,844 shares.
1. CEO Martine Rothblatt Sale
On March 16, 2026, Chairperson and CEO Martine Rothblatt sold 516 shares of United Therapeutics at $534.99 each, reducing her stake to 8,414 shares. The transaction generated proceeds of approximately $276,000 and reflects a modest repositioning within her overall holdings.
2. Director and EVP Insider Transactions
Director Ray Kurzweil sold 4,910 shares on March 4 at an average price of $489.02, cutting his holdings by 28% to 12,670 shares. Executive Vice President Paul Mahon sold 8,300 shares on March 5 at $483.16 each, an 18% reduction that left him with 36,844 shares valued near $17.8 million.
3. Stock Performance and Valuation Context
Following these filings, United Therapeutics shares opened at $478.16, down 1.4%, trading below its 50-day average of $482.51 but above the 200-day average of $452.28. The company’s market capitalization stands near $21 billion, with a P/E ratio of 17.14 and a 12-month trading range between $266.98 and $537.19.